Illumina Inc. said the Chinese government has lifted a ban on the company selling its DNA sequencing machines inside the ...

Genomics company Illumina (NASDAQ:ILMN) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

Discover key Q3 2025 earnings insights for Illumina, including raised outlook, NovaSeq X growth, and margin expansion.

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, today emerged from stealth with $6.7 million ...

Key opportunities in the precision oncology market include the rising adoption of personalized therapies, growth in ...

Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on ...

In June 2025, the US Food and Drug Administration (FDA) issued a final guidance titled Cybersecurity in Medical Devices: ...

Investing.com -- Illumina Inc (NASDAQ:ILMN) reported better-than-expected third-quarter results on Thursday, with earnings surpassing analyst estimates and the company raising its full-year outlook, ...

Illumina (($ILMN)) has held its Q3 earnings call. Read on for the main highlights of the call. Illumina’s recent earnings call painted a picture ...